Metamizol Combix (Metamizole Magnesium)

• Metamizol Combix, a pyrazolone analgesic and antipyretic, is employed to manage several acute pain and fever conditions.
• Acute pain: rapid relief of moderate to severe pain of sudden onset, such as injury‑related discomfort.
• Post‑operative pain: helps control pain following surgical procedures, facilitating early mobilization and recovery.
• Fever: reduces elevated body temperature associated with infection or inflammation, improving patient comfort.
• Colic and spasmolytic relief: eases abdominal cramping and smooth‑muscle spasms, providing symptomatic relief in gastrointestinal colic.

• Metamizole Magnesium inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis, and simultaneously modulates central pain pathways within the spinal cord and brain. This dual action diminishes peripheral inflammation and alters nociceptive signal processing, resulting in both analgesic and antipyretic effects without significant anti‑inflammatory activity typical of traditional NSAIDs.

Metamizol Combix may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild stomach upset often transient.
• Vomiting: occasional emesis after dosing.
• Dizziness: light‑headed sensation, usually short‑lived.
• Skin rash: mild erythema or itching.
• Hypotension: occasional drop in blood pressure, usually mild.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells, may lead to infection.
• Stevens‑Johnson syndrome: rare but life‑threatening skin reaction.
• Anaphylaxis: acute allergic response requiring immediate medical attention.
• Hepatic failure: rare liver injury presenting with jaundice and elevated enzymes.

• When prescribing Metamizol Combix, clinicians should consider several precautionary measures to ensure patient safety.
• Renal function: assess before use in patients with renal impairment.
• Hepatic function: monitor liver enzymes in patients with liver disease.
• Hematologic monitoring: perform blood counts due to risk of agranulocytosis.
• Allergy: avoid in patients with known hypersensitivity to pyrazolones.
• Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Metamizol Combix can interact with other medicines, and some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Concurrent use with other myelosuppressive agents: increased risk of agranulocytosis.
• Combination with ACE inhibitors or diuretics: may potentiate hypotensive effects.
• Co‑administration with other NSAIDs or COX inhibitors: heightened risk of renal toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, monitor INR.
• Lithium: possible increase in lithium levels, monitor serum concentration.
• Corticosteroids: may increase risk of gastrointestinal irritation.